<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Heart J</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-id journal-id-type="hwp">ehj</journal-id><journal-title-group><journal-title>European Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22297124</article-id><article-id pub-id-type="pmc">3533918</article-id><article-id pub-id-type="doi">10.1093/eurheartj/ehr504</article-id><article-id pub-id-type="publisher-id">ehr504</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject><subj-group subj-group-type="heading"><subject>Heart Failure/Cardiomyopathy</subject></subj-group></subj-group></article-categories><title-group><article-title>The effect of intravenous ferric carboxymaltose on health-related quality of
life in patients with chronic heart failure and iron deficiency: a subanalysis of the
FAIR-HF study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Comin-Colet</surname><given-names>Josep</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lainscak</surname><given-names>Mitja</given-names></name><xref ref-type="aff" rid="af3">3</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dickstein</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="af5">5</xref><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Filippatos</surname><given-names>Gerasimos S.</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000fc;scher</surname><given-names>Thomas F.</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Willenheimer</surname><given-names>Ronnie</given-names></name><xref ref-type="aff" rid="af10">10</xref><xref ref-type="aff" rid="af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Ponikowski</surname><given-names>Piotr</given-names></name><xref ref-type="aff" rid="af12">12</xref><xref ref-type="aff" rid="af13">13</xref></contrib><contrib contrib-type="author"><name><surname>Anker</surname><given-names>Stefan D.</given-names></name><xref ref-type="aff" rid="af4">4</xref><xref ref-type="aff" rid="af14">14</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Heart Failure Programme, Department of Cardiology,
and Research in Inflammatory and Cardiovascular Disorders Programme</addr-line>,
<institution>IMIM&#x02013;Hospital del Mar (Parc de Salut Mar)</institution>,
<addr-line>Passeig Maritim, 25&#x02013;29, 08003, Barcelona</addr-line>,
<country>Spain</country></aff><aff id="af2"><label>2</label><addr-line>Department of Medicine</addr-line>,
<institution>Universitat Autonoma de Barcelona</institution>,
<addr-line>Barcelona</addr-line>, <country>Spain</country></aff><aff id="af3"><label>3</label><addr-line>Division of Cardiology</addr-line>,
<institution>University Clinic of Respiratory and Allergic Diseases</institution>,
<addr-line>Golnik</addr-line>, <country>Slovenia</country></aff><aff id="af4"><label>4</label><addr-line>Applied Cachexia Research, Department of
Cardiology</addr-line>, <institution>Charit&#x000e9; Campus Virchow-Klinikum</institution>,
<addr-line>Berlin</addr-line>, <country>Germany</country></aff><aff id="af5"><label>5</label><institution>Stavanger University Hospital</institution>,
<addr-line>Stavanger</addr-line>, <country>Norway</country></aff><aff id="af6"><label>6</label><institution>University of Bergen</institution>,
<addr-line>Bergen</addr-line>, <country>Norway</country></aff><aff id="af7"><label>7</label><institution>Athens University Hospital Attikon</institution>,
<addr-line>Athens</addr-line>, <country>Greece</country></aff><aff id="af8"><label>8</label><institution>Vifor Pharma Ltd.</institution>,
<addr-line>Glattbrugg</addr-line>, <country>Switzerland</country></aff><aff id="af9"><label>9</label><addr-line>Department of Cardiology, Cardiovascular
Center</addr-line>, <institution>University Hospital Z&#x000fc;rich</institution>,
<addr-line>Zurich</addr-line>, <country>Switzerland</country></aff><aff id="af10"><label>10</label><institution>Heart Health Group</institution>,
<addr-line>Malm&#x000f6;</addr-line>, <country>Sweden</country></aff><aff id="af11"><label>11</label><institution>Lund University</institution>,
<addr-line>Malm&#x000f6;</addr-line>, <country>Sweden</country></aff><aff id="af12"><label>12</label><institution>Wroclaw Medical University</institution>,
<addr-line>Wroclaw</addr-line>, <country>Poland</country></aff><aff id="af13"><label>13</label><institution>Military Hospital</institution>,
<addr-line>Wroclaw</addr-line>, <country>Poland</country></aff><aff id="af14"><label>14</label><addr-line>Centre for Clinical and Basic Research</addr-line>,
<institution>IRCCS San Raffaele</institution>, <addr-line>Rome</addr-line>,
<country>Italy</country></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel: +34 932483118,
Fax: +34 932483398, Email: <email>jcomin@hospitaldelmar.cat</email></corresp><fn fn-type="con"><p>
<bold>This paper was guest-edited by William T. Abraham, Professor of Medicine,
Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210-1252,
USA</bold>
</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>31</day><month>1</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>34</volume><issue>1</issue><fpage>30</fpage><lpage>38</lpage><history><date date-type="received"><day>8</day><month>8</month><year>2011</year></date><date date-type="rev-recd"><day>5</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Published on behalf of the European Society of Cardiology. All rights
reserved. &#x000a9; The Author 2012</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>),
which permits unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ehr504.pdf"/><abstract><sec><title>Aims</title><p>Patients with chronic heart failure (CHF) show impaired health-related quality of life
(HRQoL), an important target for therapeutic intervention. Impaired iron homeostasis may
be one mechanism underlying the poor physical condition of CHF patients. This detailed
subanalysis of the previously published FAIR-HF study evaluated baseline HRQoL in
iron-deficient patients with CHF and the effect of intravenous ferric carboxymaltose
(FCM) on HRQoL.</p></sec><sec><title>Methods and results</title><p>FAIR-HF randomized 459 patients with reduced left ventricular ejection fraction and
iron deficiency, with or without anaemia, to FCM or placebo (2:1). Health-related
quality of life was assessed at baseline and after 4, 12, and 24 weeks of therapy using
the generic EQ-5D questionnaire and disease-specific Kansas City Cardiomyopathy
Questionnaire (KCCQ). Baseline mean Visual Analogue Scale (VAS) score was 54.3 &#x000b1;
16.4 and KCCQ overall summary score was 52.4 &#x000b1; 18.8. Ferric carboxymaltose
significantly improved VAS and KCCQ (mean differences from baseline in KCCQ overall,
clinical and total symptom scores, <italic>P</italic>&#x0003c; 0.001 vs. placebo) at all
time points. At Week 24, significant improvement vs. placebo was observed in four of the
five EQ-5D dimensions: mobility (<italic>P</italic>= 0.004), self-care
(<italic>P</italic>&#x0003c; 0.001), pain/discomfort (<italic>P</italic>=
0.006), anxiety/depression (<italic>P</italic>= 0.012), and usual activity
(<italic>P</italic>= 0.035). Ferric carboxymaltose improved all KCCQ domain
mean scores from Week 4 onward (<italic>P</italic>&#x02264; 0.05), except for
self-efficacy and social limitation. Effects were present in both anaemic and
non-anaemic patients.</p></sec><sec><title>Conclusions</title><p>HRQoL is impaired in iron-deficient patients with CHF. Intravenous FCM significantly
improved HRQoL after 4 weeks, and throughout the remaining study period. The positive
effects of FCM were independent of anaemia status.</p></sec></abstract><kwd-group><kwd>Anaemia</kwd><kwd>Chronic heart failure</kwd><kwd>Health-related quality of life</kwd><kwd>Iron deficiency</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Patients with chronic heart failure (CHF) suffer from a marked impairment of health-related
quality of life (HRQoL) compared with the normal population and patients with other chronic
conditions.<sup><xref ref-type="bibr" rid="EHR504C1">1</xref>&#x02013;<xref ref-type="bibr" rid="EHR504C3">3</xref></sup> Among the factors associated with a
reduced HRQoL, dyspnoea and fatigue are major symptoms of CHF that persist in many patients
despite optimal drug and device management.<sup><xref ref-type="bibr" rid="EHR504C4">4</xref></sup> Limited options for treatment of underlying CHF pathology have caused
the focus of therapeutic attention to shift towards patient-centred outcomes such as HRQoL,
particularly in those already receiving evidence-based therapy and even more so in those
with limited life expectancy.<sup><xref ref-type="bibr" rid="EHR504C5">5</xref>,<xref ref-type="bibr" rid="EHR504C6">6</xref></sup> Currently, an improvement in
patient-reported outcomes is considered one of the main goals of comprehensive CHF
management.<sup><xref ref-type="bibr" rid="EHR504C7">7</xref>&#x02013;<xref ref-type="bibr" rid="EHR504C9">9</xref></sup> Moreover, despite their benefits in
survival, some of the usual therapies used in CHF, such as beta-blockers, have failed to
prove a positive effect in terms of HRQoL.<sup><xref ref-type="bibr" rid="EHR504C10">10</xref></sup></p><p>Iron plays a vital role in energy-dependent physiological processes such as erythropoiesis
and oxidative phosphorylation,<sup><xref ref-type="bibr" rid="EHR504C11">11</xref>,<xref ref-type="bibr" rid="EHR504C12">12</xref></sup> and iron deficiency (ID) may be a
frequent and significant comorbidity in CHF.<sup><xref ref-type="bibr" rid="EHR504C13">13</xref></sup> Beyond anaemia, ID is a determinant of fatigue and impaired exercise
capacity in otherwise healthy populations.<sup><xref ref-type="bibr" rid="EHR504C14">14</xref>,<xref ref-type="bibr" rid="EHR504C15">15</xref></sup> In this context, there
is recent evidence that ID in CHF patients is also associated with impaired exercise
capacity, worse functional New York Heart Association (NYHA) class, and poorer outcomes,
although this latter observation remains controversial.<sup><xref ref-type="bibr" rid="EHR504C13">13</xref>,<xref ref-type="bibr" rid="EHR504C16">16</xref>,<xref ref-type="bibr" rid="EHR504C17">17</xref></sup> Iron deficiency is, therefore, a
potential treatment target to improve HRQoL in CHF patients.<sup><xref ref-type="bibr" rid="EHR504C11">11</xref>,<xref ref-type="bibr" rid="EHR504C18">18</xref></sup></p><p>Beyond small studies, there is little information about HRQoL in iron-deficient CHF
patients and the potential benefits of iron repletion therapy. The FAIR-HF study (Ferric
carboxymaltose Assessment in patients with IRon deficiency and chronic Heart Failure) was
designed to determine the effects of intravenous (i.v.) ferric carboxymaltose (FCM) in
iron-deficient CHF patients.<sup><xref ref-type="bibr" rid="EHR504C18">18</xref></sup>
Ferric carboxymaltose was well tolerated and significantly improved CHF symptoms, exercise
capacity, and HRQoL.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> In the
current study, we undertook a detailed subanalysis of FAIR-HF to gain specific insight into
the effects of FCM on different domains of HRQoL in iron-deficient CHF patients.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>The rationale and design of the FAIR-HF study has been previously published.<sup><xref ref-type="bibr" rid="EHR504C18">18</xref></sup> Briefly, FAIR-HF was a randomized,
double-blind, placebo-controlled, 24-week study of the effects of i.v. FCM
[Ferinject&#x000ae;, Vifor (International), Inc., St Gallen, Switzerland] in iron-deficient
patients with CHF due to systolic dysfunction, with or without anaemia. The main study
inclusion criteria were NYHA class II/III, the left ventricular ejection fraction (LVEF)
&#x02264;40% (NYHA II) or &#x02264;45% (NYHA III), haemoglobin (Hb) levels
between 9.5 and 13.5 g/dL, and ID [defined as serum ferritin &#x0003c;100 &#x000b5;g/L, or
as serum ferritin &#x0003c;300 &#x000b5;g/L if transferrin saturation (TSAT) was
&#x0003c;20%].</p><p>After 24 weeks of therapy, the patients in the FCM group experienced a significant
improvement in the Patient Global Assessment (PGA) score, NYHA class (co-primary
endpoints) and 6-minute walking test distance (secondary endpoint) compared with patients
receiving placebo.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup></p></sec><sec id="s2b"><title>Health-related quality of life measurements</title><p>Two standard instruments were used: the disease-specific Kansas City Cardiomyopathy
Questionnaire (KCCQ) and the generic EuroQoL EQ-5D questionnaire.</p><p>The KCCQ<sup><xref ref-type="bibr" rid="EHR504C20">20</xref></sup> is a disease-specific
measure of HRQoL for heart failure comprising seven domains (physical limitation, symptom
stability, symptom burden, symptom frequency, self-efficacy, quality of life, and social
limitation) and three summary scores [total symptom score (TSS, comprising symptom
frequency and symptom burden), overall summary score (OSS, comprising physical limitation,
TSS, quality of life and social limitation), and clinical summary score (CSS, comprising
physical limitation, TSS)]. Scores ranged between 0 and 100, where 100 is the best
possible HRQoL status. A five-unit change in the OSS was defined as the minimally
noticeable clinical difference in response to treatment.<sup><xref ref-type="bibr" rid="EHR504C21">21</xref></sup></p><p>The EQ-5D instrument<sup><xref ref-type="bibr" rid="EHR504C9">9</xref></sup> is a generic
measure of HRQoL, comprising a Visual Analogue Scale (VAS) for self-rating of general
health (a score of 100 is the best possible general health status) and five domains
evaluating mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
In this instrument, 1 is the best possible general health status in each case; the
dimensions may also be expressed as percentage of patients rating 1&#x02013;3 (best to
worst health status) or percentage of patients with &#x02018;any&#x02019; complaint (scoring
2 or 3 in each domain). The results for the five domains can be converted into a single
summary index score by weighting the individual values and deducting the weighted values
from 1, the value for full health (i.e. state 11111). In this study, the index was
multiplied by 100. The minimally important difference (MID) in the EQ-5D index score is
defined as the smallest change in the index score that can be regarded as important and
meaningful for health professionals, patients, and other stakeholders. Based on data from
11 patient groups in eight longitudinal studies, the MID has been estimated to be 0.074
(7.4%).<sup><xref ref-type="bibr" rid="EHR504C9">9</xref>,<xref ref-type="bibr" rid="EHR504C22">22</xref></sup></p><p>During the FAIR-HF study, the EQ-5D questionnaire and the KCCQ were self-administered at
baseline, and at Weeks 4, 12, and 24, before any other assessment or procedure.</p></sec><sec id="s2c"><title>Statistical analysis</title><p>Data analysis was performed using the full analysis set based on the intention-to-treat
principle for each assigned study group. We used a two-tailed significance level of
&#x003b1; = 0.05 for all assessments. We present data at baseline as mean &#x000b1;
SD or number (per cent). Health-related quality of life data are presented as mean
&#x000b1; SEM.</p><p>For the continuous variables, changes from the baseline value and values at Weeks 4, 12,
and 24 were compared between the FCM group and the placebo group by means of repeated
measures analysis of covariance. The statistical model included treatment group, visit and
their interaction as categorical variables and baseline value as a continuous covariate.
An unstructured covariance matrix was used.</p><p>For categorical endpoints, differences in the distribution of the two study groups were
tested by means of ordered polytomous regression for repeated measures. The same
explanatory variables were used as in the analyses of continuous endpoints, and an
unstructured covariance matrix was used.</p><p>Missing HRQoL data at each time point were defined as the following: no EQ-5D VAS score,
no EQ-5D index score, or no KCCQ OSS. Missing data for patients known to be alive and not
hospitalized at the time point being analysed were imputed using the &#x02018;last
observation carried forward&#x02019; method, for which at least one previous follow-up
value was required. If no preceding HRQoL values were available, the patient was excluded
in that analysis. For hospitalized patients unable to complete the questionnaires, or if
the patient had died between the last time point and the planned time point, the worst
reply was used for the imputation (i.e 1 for the KCCQ individual domains, 3 for the EQ-5D
sub-questions, and 0 for the EQ-5D VAS score).</p><p>The effects of baseline characteristics on baseline HRQoL were assessed by means of
analysis of covariance models. Using simple backward elimination, non-significant
variables (<italic>P</italic>&#x0003e; 0.10) were removed from the model one at a time.
Tests for interaction (e.g. treatment-by-baseline NYHA) were performed by analysing the
data by visit and adding the interaction term to the statistical models. All analyses were
conducted with the SAS software, version 9.1 (SAS Institute, Inc., Cary, NC, USA:
2000&#x02013;2004).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>The screening and inclusion process for eligible patients, baseline characteristics, and
primary and secondary endpoint results have been published.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> Here, we present otherwise unpublished specific HRQoL
analyses, and only show previously published data, appropriately cited, when they are
required to understand the current analyses.</p><p>The two treatment groups were well matched for patient demographic, laboratory parameters,
and treatment characteristics. At the start of the study, the mean (&#x000b1;SD) age was 67.8
&#x000b1; 10.3 and 67.4 &#x000b1; 11.1 years in the FCM and placebo groups, respectively. In
the FCM group, 52.3% of patients were women, compared with 54.8% in the
placebo group.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> All patients were
in either NYHA class II or II, with 83% in the FCM group and 81% in the
placebo group in NYHA class III.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup>
The FCM and placebo groups, respectively, were well matched for mean (&#x000b1;SD) %
LVEF (32.5 &#x000b1; 5 and 33 &#x000b1; 6) and the Hb level (11.9 &#x000b1; 1.3 and 11.9
&#x000b1; 1.4 g/dL).<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> In both
groups, 48% of patients were anaemic (Hb &#x02264;12 g/dL).<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup></p><p>Health-related quality of life data were available for over 90 per cent of patients at all
time points. The two groups had similar HRQoL scores at baseline as measured by EQ-5D VAS
score, index score, and domains, and by the KCCQ summary scores and domain scores
(<italic>Table&#x000a0;<xref ref-type="table" rid="EHR504TB1">1</xref></italic>).
<table-wrap id="EHR504TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline health-related quality of life</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">HRQoL: EQ-5D</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Visual analogue scale</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Missing data, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">9 (3)</td><td rowspan="1" colspan="1">3 (2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Mean &#x000b1; SEM</td><td rowspan="1" colspan="1">54 &#x000b1; 1</td><td rowspan="1" colspan="1">54 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Index score (&#x000d7;100)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Missing data, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">6 (2)</td><td rowspan="1" colspan="1">1 (1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Mean &#x000b1; SEM</td><td rowspan="1" colspan="1">68 &#x000b1; 1</td><td rowspan="1" colspan="1">69 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Patients reporting any problem by domain</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Mobility, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">245 (81)</td><td rowspan="1" colspan="1">131 (85)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Self-care, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">146 (49)</td><td rowspan="1" colspan="1">79 (51)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Usual activity, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">232 (77)</td><td rowspan="1" colspan="1">124 (81)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Pain/discomfort, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">228 (76)</td><td rowspan="1" colspan="1">117 (75)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Anxiety/depression, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">194 (65)</td><td rowspan="1" colspan="1">97 (63)</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="3" rowspan="1">HRQoL: KCCQ</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">7 (2)</td><td rowspan="1" colspan="1">4 (3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Overall summary score, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">52 &#x000b1; 1</td><td rowspan="1" colspan="1">53 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Clinical summary score, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">55 &#x000b1; 1</td><td rowspan="1" colspan="1">55 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total symptom score, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">59 &#x000b1; 1</td><td rowspan="1" colspan="1">59 &#x000b1; 2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Physical limitation, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">52 &#x000b1; 1</td><td rowspan="1" colspan="1">52 &#x000b1; 2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Symptom burden, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">59 &#x000b1; 1</td><td rowspan="1" colspan="1">60 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Symptom frequency, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">59 &#x000b1; 1</td><td rowspan="1" colspan="1">58 &#x000b1; 2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Symptom stability, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">54 &#x000b1; 1</td><td rowspan="1" colspan="1">53 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Self-efficacy, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">64 &#x000b1; 1</td><td rowspan="1" colspan="1">63 &#x000b1; 2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Quality of life, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">47 &#x000b1; 1</td><td rowspan="1" colspan="1">48 &#x000b1; 2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Social limitation, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">51 &#x000b1; 2</td><td rowspan="1" colspan="1">51 &#x000b1; 2</td></tr></tbody></table><table-wrap-foot><fn><p>Visual Analogue Scale and Kansas City Cardiomyopathy Questionnaire overall
summary score data were previously published, and are included here for
context.<sup><xref ref-type="bibr" rid="EHR504C16">16</xref></sup></p></fn><fn><p>KCCQ, Kansas City Cardiomyopathy Questionnaire.</p></fn></table-wrap-foot></table-wrap></p><sec id="s3a"><title>Baseline health-related quality of life in chronic heart failure patients</title><p>At baseline, HRQoL was lower in patients with anaemia compared with non-anaemic patients
(<italic>Table&#x000a0;<xref ref-type="table" rid="EHR504TB2">2</xref></italic>).
Likewise, symptom severity (NYHA class III vs. II) was associated with incrementally worse
HRQoL (<italic>Table&#x000a0;<xref ref-type="table" rid="EHR504TB2">2</xref></italic>).
<table-wrap id="EHR504TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Differences in baseline health-related quality of life according to anaemia
status and NYHA class</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Anaemic (<italic>n</italic>= 220)</th><th align="left" rowspan="1" colspan="1">Non-anaemic (<italic>n</italic>= 221)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> (anaemic vs. non-anaemic)</th><th align="left" rowspan="1" colspan="1">NYHA III (<italic>n</italic>= 377)</th><th align="left" rowspan="1" colspan="1">NYHA II (<italic>n</italic>= 82)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> (NYHA III vs. NYHA II)</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">HRQoL: EQ-5D</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Visual Analogue Scale, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">53.0 &#x000b1; 1.1</td><td rowspan="1" colspan="1">55.6 &#x000b1; 1.1</td><td rowspan="1" colspan="1">0.093</td><td rowspan="1" colspan="1">52.5 &#x000b1; 0.8</td><td rowspan="1" colspan="1">62.4 &#x000b1; 1.9</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Index score (&#x000d7;100), mean &#x000b1; SEM)</td><td rowspan="1" colspan="1">66.2 &#x000b1; 1.0</td><td rowspan="1" colspan="1">70.7 &#x000b1; 1.1</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">66.7 &#x000b1; 0.8</td><td rowspan="1" colspan="1">76.5 &#x000b1; 1.6</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td colspan="7" rowspan="1">HRQoL: KCCQ</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Overall summary score, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">49.3 &#x000b1; 1.2</td><td rowspan="1" colspan="1">55.7 &#x000b1; 1.3</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">49.4 &#x000b1; 0.9</td><td rowspan="1" colspan="1">66.8 &#x000b1; 1.9</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Clinical summary score, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">52.4 &#x000b1; 1.2</td><td rowspan="1" colspan="1">58.6 &#x000b1; 1.3</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">52.0 &#x000b1; 0.9</td><td rowspan="1" colspan="1">71.8 &#x000b1; 1.8</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total symptom score, mean &#x000b1; SEM</td><td rowspan="1" colspan="1">56.3 &#x000b1; 1.3</td><td rowspan="1" colspan="1">61.6 &#x000b1; 1.4</td><td rowspan="1" colspan="1">&#x0003c;0.005</td><td rowspan="1" colspan="1">55.5 &#x000b1; 1.0</td><td rowspan="1" colspan="1">75.2 &#x000b1; 1.9</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>NYHA, New York Heart Association; EQ-5D, Euro QoL 5 Dimensions; KCCQ, Kansas
City Cardiomyopathy Questionnaire.</p></fn></table-wrap-foot></table-wrap></p><p>Age at baseline, gender, baseline NYHA, ischaemic aetiology of CHF, baseline serum iron,
serum ferritin, TSAT, and Hb were associated with baseline QoL scores in the univariate
analyses. We fitted an analysis of covariance model with a range of these possible
predictors. Through backward elimination, non-significant variables were removed. In the
final model, baseline NYHA class (<italic>P</italic>&#x0003c; 0.001), baseline Hb
(<italic>P</italic>= 0.02), and baseline TSAT (<italic>P</italic>= 0.04)
were associated with HRQoL (KCCQ OSS).</p></sec><sec id="s3b"><title>Effect of intravenous ferric carboxymaltose on health-related quality of life</title><p>As previously published, FCM significantly improved EQ-5D VAS and KCCQ OSS.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> In our analysis, we found that FCM
also improved EQ-5D index scores, and other summary scores of the KCCQ, such as CSS and
TSS consistently after 4 weeks of treatment initiation. These effects were maintained or
increased throughout the study (FCM <italic>P</italic>&#x0003c; 0.001 vs. placebo at each
time point, <italic>Tables&#x000a0;<xref ref-type="table" rid="EHR504TB3">3</xref></italic>
and <italic><xref ref-type="table" rid="EHR504TB4">4</xref></italic>). The changes from
baseline in EQ-5D VAS and index scores ranged on average between 13 and 25%
throughout the study, compared with &#x0003c;10% among the placebo group
(<italic>Table&#x000a0;<xref ref-type="table" rid="EHR504TB3">3</xref></italic>).
<table-wrap id="EHR504TB3" position="float"><label>Table&#x000a0;3</label><caption><p>Absolute and percentage change from baseline in generic quality of life
measured using the EQ-5D instrument</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="left" colspan="2" rowspan="1">Week 4<hr/></th><th align="left" colspan="2" rowspan="1">Week 12<hr/></th><th align="left" colspan="2" rowspan="1">Week 24<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">EQ-5D Visual Analogue Scale</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">30 (9.9)</td><td rowspan="1" colspan="1">15 (9.7)</td><td rowspan="1" colspan="1">21 (6.9)</td><td rowspan="1" colspan="1">10 (6.5)</td><td rowspan="1" colspan="1">19 (6.3)</td><td rowspan="1" colspan="1">9 (5.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean &#x000b1; SEM (% change from baseline)</td><td rowspan="1" colspan="1">6.0 &#x000b1; 0.7 (17.4 &#x000b1; 2.1)***</td><td rowspan="1" colspan="1">0.8 &#x000b1; 1.3 (4.8 &#x000b1; 2.8)</td><td rowspan="1" colspan="1">7.9 &#x000b1; 0.8 (21.4 &#x000b1; 2.3)***</td><td rowspan="1" colspan="1">2.4 &#x000b1; 1.5 (7.9 &#x000b1; 3.2)</td><td rowspan="1" colspan="1">9.1 &#x000b1; 1.0 (24.6 &#x000b1; 2.7)***</td><td rowspan="1" colspan="1">3.4 &#x000b1; 1.6 (9.9 &#x000b1; 3.3)</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td colspan="7" rowspan="1">EQ-5D index score</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">29 (9.5)</td><td rowspan="1" colspan="1">13 (8.4)</td><td rowspan="1" colspan="1">17 (5.6)</td><td rowspan="1" colspan="1">8 (5.2)</td><td rowspan="1" colspan="1">16 (5.3)</td><td rowspan="1" colspan="1">7 (4.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean &#x000b1; SEM, &#x000d7;100 (% change from baseline)</td><td rowspan="1" colspan="1">5.9 &#x000b1; 0.8 (12.6 &#x000b1; 1.8)***</td><td rowspan="1" colspan="1">0.6 &#x000b1; 1.5 (5.1 &#x000b1; 2.8)</td><td rowspan="1" colspan="1">6.9 &#x000b1; 1.0 (15.1 &#x000b1; 2.2)***</td><td rowspan="1" colspan="1">&#x02212;1.6 &#x000b1; 1.7 (0.5 &#x000b1; 3.3)</td><td rowspan="1" colspan="1">6.6 &#x000b1; 1.2 (14.4 &#x000b1; 2.5)***</td><td rowspan="1" colspan="1">&#x02212;1.0 &#x000b1; 1.8 (1.5 &#x000b1; 3.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mobility, <italic>n</italic> (%) reporting improvement</td><td rowspan="1" colspan="1">46 (16.5)</td><td rowspan="1" colspan="1">15 (10.4)</td><td rowspan="1" colspan="1">55 (19.0)***</td><td rowspan="1" colspan="1">9 (6.1)</td><td rowspan="1" colspan="1">59 (20.3)**</td><td rowspan="1" colspan="1">17 (11.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Self-care, <italic>n</italic> (%) reporting improvement</td><td rowspan="1" colspan="1">43 (15.5)**</td><td rowspan="1" colspan="1">14 (9.8)</td><td rowspan="1" colspan="1">54 (18.8)***</td><td rowspan="1" colspan="1">17 (11.6)</td><td rowspan="1" colspan="1">61 (21.1)***</td><td rowspan="1" colspan="1">14 (9.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Usual activity, <italic>n</italic> (%) reporting
improvement</td><td rowspan="1" colspan="1">53 (18.9)*</td><td rowspan="1" colspan="1">18 (12.7)</td><td rowspan="1" colspan="1">62 (21.4)</td><td rowspan="1" colspan="1">23 (15.6)</td><td rowspan="1" colspan="1">70 (24.1)*</td><td rowspan="1" colspan="1">23 (15.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pain/discomfort, <italic>n</italic> (%) reporting
improvement</td><td rowspan="1" colspan="1">57 (20.3)*</td><td rowspan="1" colspan="1">21 (14.7)</td><td rowspan="1" colspan="1">77 (26.6)***</td><td rowspan="1" colspan="1">22 (14.9)</td><td rowspan="1" colspan="1">82 (28.2)**</td><td rowspan="1" colspan="1">25 (16.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Anxiety/depression, <italic>n</italic> (%) reporting
improvement</td><td rowspan="1" colspan="1">68 (24.3)</td><td rowspan="1" colspan="1">30 (21.0)</td><td rowspan="1" colspan="1">84 (29.1)*</td><td rowspan="1" colspan="1">33 (22.3)</td><td rowspan="1" colspan="1">94 (32.4)*</td><td rowspan="1" colspan="1">37 (24.8)</td></tr></tbody></table><table-wrap-foot><fn><p>Visual Analogue Scale data were previously published, and are included here for
context.<sup><xref ref-type="bibr" rid="EHR504C16">16</xref></sup></p></fn><fn><p>*<italic>P</italic>&#x0003c; 0.05;
**<italic>P</italic>&#x0003c; 0.01;
***<italic>P</italic>&#x0003c; 0.001 for ferric
carboxymaltose vs. placebo.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="EHR504TB4" position="float"><label>Table&#x000a0;4</label><caption><p>Absolute and percentage change from baseline in heart-failure-specific
quality of life measured using the Kansas City Cardiomyopathy
Questionnaire</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="left" colspan="2" rowspan="1">Week 4<hr/></th><th align="left" colspan="2" rowspan="1">Week 12<hr/></th><th align="left" colspan="2" rowspan="1">Week 24<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th><th align="left" rowspan="1" colspan="1">FCM (<italic>n</italic>= 304)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>= 155)</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">HRQoL: KCCQ</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing data, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">27 (8.9)</td><td rowspan="1" colspan="1">15 (9.7)</td><td rowspan="1" colspan="1">18 (5.9)</td><td rowspan="1" colspan="1">11 (7.1)</td><td rowspan="1" colspan="1">18 (5.9)</td><td rowspan="1" colspan="1">10 (6.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Overall summary score, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">9.4 &#x000b1; 0.9 (33.6 &#x000b1; 5.2)***</td><td rowspan="1" colspan="1">3.5 &#x000b1; 1.2 (10.6 &#x000b1; 3.3)</td><td rowspan="1" colspan="1">12.2 &#x000b1; 1.1 (41.9 &#x000b1; 5.8)***</td><td rowspan="1" colspan="1">4.6 &#x000b1; 1.4 (16.1 &#x000b1; 5.4)</td><td rowspan="1" colspan="1">12.8 &#x000b1; 1.3 (43.9 &#x000b1; 6.1)***</td><td rowspan="1" colspan="1">6.2 &#x000b1; 1.5 (21.5 &#x000b1; 6.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Clinical summary score, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">9.3 &#x000b1; 0.9 (29.9 &#x000b1; 4.3)***</td><td rowspan="1" colspan="1">2.7 &#x000b1; 1.2 (7.0 &#x000b1; 2.5)</td><td rowspan="1" colspan="1">11.6 &#x000b1; 1.1 (36.2 &#x000b1; 4.7)***</td><td rowspan="1" colspan="1">3.3 &#x000b1; 1.4 (9.4 &#x000b1; 3.5)</td><td rowspan="1" colspan="1">11.4 &#x000b1; 1.3 (36.8 &#x000b1; 4.9)***</td><td rowspan="1" colspan="1">4.2 &#x000b1; 1.5 (12.6 &#x000b1; 3.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total symptom score, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">10.4 &#x000b1; 1.0 (34.1 &#x000b1; 5.1)***</td><td rowspan="1" colspan="1">3.1 &#x000b1; 1.2 (7.5 &#x000b1; 2.6)</td><td rowspan="1" colspan="1">12.7 &#x000b1; 1.2 (38.0 &#x000b1; 4.4)***</td><td rowspan="1" colspan="1">3.3 &#x000b1; 1.5 (8.2 &#x000b1; 3.3)</td><td rowspan="1" colspan="1">12.0 &#x000b1; 1.3 (36.3 &#x000b1; 4.5)***</td><td rowspan="1" colspan="1">3.9 &#x000b1; 1.6 (11.5 &#x000b1; 3.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Physical limitation, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">8.2 &#x000b1; 1.1 (31.7 &#x000b1; 4.7)***</td><td rowspan="1" colspan="1">2.3 &#x000b1; 1.4 (9.8 &#x000b1; 3.7)</td><td rowspan="1" colspan="1">10.5 &#x000b1; 1.3 (39.5 &#x000b1; 5.9)***</td><td rowspan="1" colspan="1">3.3 &#x000b1; 1.6 (11.8 &#x000b1; 4.2)</td><td rowspan="1" colspan="1">10.7 &#x000b1; 1.5 (45.5 &#x000b1; 7.1)**</td><td rowspan="1" colspan="1">4.5 &#x000b1; 1.8 (13.5 &#x000b1; 4.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Symptom frequency, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">10.1 &#x000b1; 1.1 (40.9 &#x000b1; 8.8)***</td><td rowspan="1" colspan="1">4.1 &#x000b1; 1.4 (12.2 &#x000b1; 3.4)</td><td rowspan="1" colspan="1">12.0 &#x000b1; 1.2 (44.2 &#x000b1; 7.9)***</td><td rowspan="1" colspan="1">3.2 &#x000b1; 1.5 (10.2 &#x000b1; 3.9)</td><td rowspan="1" colspan="1">11.5 &#x000b1; 1.4 (41.4 &#x000b1; 8.1)***</td><td rowspan="1" colspan="1">4.6 &#x000b1; 1.7 (17.6 &#x000b1; 4.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Symptom stability, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">12.7 &#x000b1; 1.4 (32.3 &#x000b1; 3.3)***</td><td rowspan="1" colspan="1">1.6 &#x000b1; 1.9 (8.9 &#x000b1; 4.4)</td><td rowspan="1" colspan="1">14.2 &#x000b1; 1.7 (37.6 &#x000b1; 3.9)***</td><td rowspan="1" colspan="1">1.7 &#x000b1; 2.1 (11.6 &#x000b1; 5.4)</td><td rowspan="1" colspan="1">13.2 &#x000b1; 1.7 (33.8 &#x000b1; 3.7)***</td><td rowspan="1" colspan="1">4.5 &#x000b1; 2.1 (17.0 &#x000b1; 5.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Symptom burden, mean &#x000b1; SEM (% change from baseline)</td><td rowspan="1" colspan="1">10.8 &#x000b1; 1.1 (35.2 &#x000b1; 5.2)***</td><td rowspan="1" colspan="1">2.1 &#x000b1; 1.3 (6.1 &#x000b1; 2.7)</td><td rowspan="1" colspan="1">13.3 &#x000b1; 1.2 (40.8 &#x000b1; 5.1)***</td><td rowspan="1" colspan="1">3.3 &#x000b1; 1.6 (9.2 &#x000b1; 3.6)</td><td rowspan="1" colspan="1">12.5 &#x000b1; 1.4 (39.0 &#x000b1; 5.1)***</td><td rowspan="1" colspan="1">3.3 &#x000b1; 1.7 (10.2 &#x000b1; 3.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Self-efficacy, mean &#x000b1; SEM (% change from baseline)</td><td rowspan="1" colspan="1">6.9 &#x000b1; 1.3 (23.5 &#x000b1; 4.3)</td><td rowspan="1" colspan="1">5.7 &#x000b1; 1.9 (23.0 &#x000b1; 7.4)</td><td rowspan="1" colspan="1">8.9 &#x000b1; 1.3 (28.8 &#x000b1; 4.8)*</td><td rowspan="1" colspan="1">4.3 &#x000b1; 2.4 (21.3 &#x000b1; 7.4)</td><td rowspan="1" colspan="1">9.7 &#x000b1; 1.5 (30.0 &#x000b1; 5.0)</td><td rowspan="1" colspan="1">6.0 &#x000b1; 2.4 (26.3 &#x000b1; 7.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Quality of life, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">8.7 &#x000b1; 1.1 (36.8 &#x000b1; 5.8)**</td><td rowspan="1" colspan="1">3.6 &#x000b1; 1.6 (19.8 &#x000b1; 7.1)</td><td rowspan="1" colspan="1">13.3 &#x000b1; 1.3 (54.9 &#x000b1; 7.0)***</td><td rowspan="1" colspan="1">4.5 &#x000b1; 1.6 (21.7 &#x000b1; 6.9)</td><td rowspan="1" colspan="1">14.8 &#x000b1; 1.4 (59.1 &#x000b1; 7.3)***</td><td rowspan="1" colspan="1">6.8 &#x000b1; 1.8 (31.8 &#x000b1; 8.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Social limitation, mean &#x000b1; SEM (% change from
baseline)</td><td rowspan="1" colspan="1">10.2 &#x000b1; 1.4 (46.6 &#x000b1; 8.5)**</td><td rowspan="1" colspan="1">4.1 &#x000b1; 1.7 (15.0 &#x000b1; 5.3)</td><td rowspan="1" colspan="1">12.1 &#x000b1; 1.6 (55.2 &#x000b1; 11.0)*</td><td rowspan="1" colspan="1">7.2 &#x000b1; 2.1 (25.4 &#x000b1; 7.1)</td><td rowspan="1" colspan="1">13.1 &#x000b1; 1.7 (54.4 &#x000b1; 9.7)</td><td rowspan="1" colspan="1">8.5 &#x000b1; 2.2 (27.5 &#x000b1; 6.9)</td></tr></tbody></table><table-wrap-foot><fn><p>KCCQ overall summary score data were previously published, and are included
here for context.<sup><xref ref-type="bibr" rid="EHR504C16">16</xref></sup></p></fn><fn><p>*<italic>P</italic>&#x0003c; 0.05;
**<italic>P</italic>&#x0003c; 0.01;
***<italic>P</italic>&#x0003c; 0.001 for ferric
carboxymaltose vs. placebo.</p></fn></table-wrap-foot></table-wrap></p><p>There was a greater improvement in the percentage of patients reporting any complaint in
each EQ-5D domain in the FCM group compared with the placebo group
(<italic>Table&#x000a0;<xref ref-type="table" rid="EHR504TB3">3</xref></italic>).
Throughout the study, significantly more (<italic>P</italic>&#x0003c; 0.02) patients
reported an MID in the FCM group (37&#x02013;45%) compared with the placebo group
(22&#x02013;29%; <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHR504F1">1</xref></italic>). In addition to overall improvement, FCM treatment was associated
with lower rates of deterioration in HRQoL reported throughout the study
(<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHR504F2">2</xref></italic>). <fig id="EHR504F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Percentage of iron-deficient chronic heart failure patients treated with
ferric carboxymaltose or placebo reporting at least a minimally important difference
in EQ-5D index score at each study time point [minimally important difference is the
smallest index score change meaningful for health professionals, patients and other
stakeholders, and is 0.074 (7.4%) for the EQ-5D index score].<sup><xref ref-type="bibr" rid="EHR504C1">1</xref>,<xref ref-type="bibr" rid="EHR504C22">22</xref></sup></p></caption><graphic xlink:href="ehr50401"/></fig>
<fig id="EHR504F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Percentage of iron-deficient chronic heart failure patients treated with
ferric carboxymaltose or placebo reporting improvement or deterioration in
health-related quality of life at study Week 24 as measured using the Kansas City
Cardiomyopathy Questionnaire (<italic>A</italic>) overall summary score,
(<italic>B</italic>) overall clinical score, and (<italic>C</italic>) total
symptom score.</p></caption><graphic xlink:href="ehr50402"/></fig></p><p>The proportion of patients experiencing a clinically significant five-point change in
KCCQ OSS at Week 24 was significantly higher in the FCM group compared with placebo
patients (61 vs. 51%; <italic>P</italic>= 0.04). The individual percentage
changes in KCCQ CSS and TSS (<italic>Table&#x000a0;<xref ref-type="table" rid="EHR504TB4">4</xref></italic>) were at least three times greater among patients receiving FCM
(30&#x02013;37%) than those receiving placebo (7.0&#x02013;12.6%), and OSS
changes were two or three times greater among the iron-treated group. Among the individual
domains, the greatest differences in percentage change between FCM and placebo groups were
seen in symptom-related domains, where improvements were mostly three or four times
greater in the FCM group than the placebo group. Likewise, iron treatment resulted in an
approximately three-fold improvement in physical limitation compared with placebo.
However, there were no major differences between groups in self-efficacy scores.</p><p>As shown in <italic>Figures&#x000a0;<xref ref-type="fig" rid="EHR504F3">3</xref></italic>
and <italic><xref ref-type="fig" rid="EHR504F4">4</xref></italic>, the effects of FCM on
HRQoL as measured by KCCQ were independent of a range of pre-specified variables,
including baseline anaemia, renal function, age, CHF aetiology, and diabetes. The efficacy
of FCM at Week 24 appeared to be affected by baseline CHF severity as indicated by NYHA
class (<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHR504F3">3</xref></italic>), an
effect also observed in the KCCQ CSS (<italic>P</italic><sub>Interaction</sub>=
0.04), TSS (<italic>P</italic><sub>Interaction</sub>= 0.03), QoL score
(<italic>P</italic><sub>Interaction</sub>= 0.01), and symptom burden score
(<italic>P</italic><sub>Interaction</sub>= 0.02). <fig id="EHR504F3" position="float"><label>Figure&#x000a0;3</label><caption><p>Effect of ferric carboxymaltose on Kansas City Cardiomyopathy Questionnaire
overall summary score among pre-specified subgroups in the FAIR-HF study population.
CHF, chronic heart failure; FCM, ferric carboxymaltose; GFR, glomerular filtration
rate; HRQoL, health-related quality of life; KCCQ, Kansas City Cardiomyopathy
Questionnaire; NYHA, New York Heart Association.</p></caption><graphic xlink:href="ehr50403"/></fig>
<fig id="EHR504F4" position="float"><label>Figure&#x000a0;4</label><caption><p>Effect (mean &#x000b1; SE) of ferric carboxymaltose on (<italic>A</italic>)
Kansas City Cardiomyopathy Questionnaire clinical summary score (CSS; integrates
total symptom score and physical limitation domain) and (<italic>B</italic>) Kansas
City Cardiomyopathy Questionnaire quality of life domain among anaemic and
non-anaemic subjects in the FAIR-HF study population.</p></caption><graphic xlink:href="ehr50404"/></fig></p><p>Although anaemia was associated with lower baseline HRQoL in patients with ID compared
with ID without anaemia, there were no significant differences between FCM treatment
effects observed in anaemic and non-anaemic patients at the end of the study (after
adjustment for baseline differences) for the KCCQ OSS (<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHR504F3">3</xref></italic>). Values at Week 24 in the FCM group
[adjusted for baseline (&#x000b1; SEM) in the anaemic and non-anaemic subgroups,
respectively] were: EQ-5D index score 74.7 &#x000b1; 1.6 vs. 75.7 &#x000b1; 1.6
(<italic>P</italic>= 0.66); EQ-5D VAS 63.1 &#x000b1; 1.3 vs. 63.8 &#x000b1; 1.3
(<italic>P</italic>= 0.74); KCCQ OSS 66.1 &#x000b1; 1.6 vs. 64.9 &#x000b1; 1.6
(<italic>P</italic>= 0.61). The absence of differences in treatment effects
according to anaemia status was also observed for other relevant domains and summary
scores of the KCCQ that specifically capture information about symptoms and physical
limitation such as KCCQ CSS, and about HRQoL, such as the KCCQ QoL domain
(<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHR504F4">4</xref></italic>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The primary analysis of the FAIR-HF study showed that FCM treatment improved overall
measures of HRQoL (EQ-5D VAS and index scores, and KCCQ OSS) in patients with CHF and ID
after 4 weeks of treatment,<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup>
confirming the findings of several smaller studies.<sup><xref ref-type="bibr" rid="EHR504C23">23</xref>&#x02013;<xref ref-type="bibr" rid="EHR504C25">25</xref></sup>
Here, we report detailed HRQoL data for baseline status and the impact of comorbidities on
the efficacy of FCM treatment.</p><p>As expected for patients with CHF, cross-study comparisons revealed a markedly reduced
baseline HRQoL in the FAIR-HF patients relative to age-matched normal populations.<sup><xref ref-type="bibr" rid="EHR504C1">1</xref>,<xref ref-type="bibr" rid="EHR504C26">26</xref></sup> Health-related quality of life impairment was strongly related to domains
most influenced by physical limitation, such as mobility and usual activities, although many
patients also reported problems in pain/discomfort and anxiety/depression domains,
highlighting the multidimensional nature of HRQoL.</p><p>The effect of FCM on HRQoL was significant throughout the study, with more patients
reporting clinically meaningful changes in the FCM treatment arm. Consistent with these
findings, the proportion of patients reporting any problems in the EQ-5D dimensions was
significantly reduced at the end of the study only in the FCM group, and fewer patients in
the FCM group experienced deteriorating HRQoL during the study, which may be important given
the progressive nature of the disease.</p><p>The positive effect of FCM in HRQoL was consistent among all pre-specified subgroups,
except for NYHA class. Although this latter observation may be, in part, attributable to the
low sample size and the apparent improvements seen in the placebo arm among patients in NYHA
class II, it may also suggest less improvement in HRQoL in patients with in a lower NYHA
class. New York Heart Association class II patients have better QoL than patients in higher
classes<sup><xref ref-type="bibr" rid="EHR504C2">2</xref></sup> and therefore
hypothetically there is less room for improvement. This interaction between NYHA class and
HRQoL was observed consistently in the specific domains and the summary scores; however,
there was no interaction between NYHA class and the 6MWT, an objective measure of functional
capacity.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> This apparent
discrepancy gives support to the evidence that the correlation between objective functional
capacity and HRQoL is not perfect and that HRQoL measures may provide additional information
not captured by more conventional ways of assessing physical limitation in patients with
CHF.<sup><xref ref-type="bibr" rid="EHR504C27">27</xref></sup></p><p>Ferric carboxymaltose was equally effective in anaemic and non-anaemic patients and the
effect was independent of baseline renal function. In the FCM group, the change was more
apparent in anaemic patients, but this could mostly be accounted for by their lower baseline
HRQoL.</p><p>The physiological mechanisms behind the favourable change in HRQoL due to FCM treatment
have not been completely elucidated. Transferrin saturation, a marker of iron availability
and probably ID at the tissue level,<sup><xref ref-type="bibr" rid="EHR504C28">28</xref></sup> was independently associated with abnormalities in HRQoL at baseline, and
further work is needed to determine the relevance of this. There is some evidence that poor
iron homeostasis is one of the mechanisms underlying exercise intolerance in CHF,<sup><xref ref-type="bibr" rid="EHR504C13">13</xref>,<xref ref-type="bibr" rid="EHR504C17">17</xref>,<xref ref-type="bibr" rid="EHR504C19">19</xref></sup> partly due to impaired
physical function as a result of ID in skeletal and myocardial muscle cells.<sup><xref ref-type="bibr" rid="EHR504C14">14</xref>,<xref ref-type="bibr" rid="EHR504C15">15</xref></sup> In this context, recent studies have shown that patients with CHF and
anaemia commonly exhibit tissue ID at the myocyte level.<sup><xref ref-type="bibr" rid="EHR504C29">29</xref></sup> Furthermore, treatment with i.v. iron may have
favourable effects in cardiac structure and remodelling.<sup><xref ref-type="bibr" rid="EHR504C30">30</xref></sup> We can therefore hypothesise that ID impairs physical
function and promotes symptoms such as fatigue due to impaired energy metabolism, a common
feature in CHF, as well as due to abnormal erythropoiesis where anaemia is
present.<sup><xref ref-type="bibr" rid="EHR504C11">11</xref>,<xref ref-type="bibr" rid="EHR504C13">13</xref>,<xref ref-type="bibr" rid="EHR504C17">17</xref>,<xref ref-type="bibr" rid="EHR504C23">23</xref></sup> These mechanisms may explain why FCM
administration significantly improved HRQoL in both anaemic and non-anaemic patients, and
why this benefit was seen early after initiation of the therapy, after just 4 weeks, despite
only a modest increase in the Hb level.</p><p>Health-related quality of life instruments capture self-perceived health and are a useful
measure of the efficacy of any therapeutic intervention from the perspective of the patient
and the treating professional. This is particularly relevant in elderly patients with CHF,
where trading longevity for improvement in physical, emotional and social well-being may be
the preference.<sup><xref ref-type="bibr" rid="EHR504C1">1</xref>,<xref ref-type="bibr" rid="EHR504C27">27</xref></sup> Also, patient-reported outcomes have been found to be
independent predictors of outcome in HF patients; therefore, HRQoL may give important
prognostic information.<sup><xref ref-type="bibr" rid="EHR504C27">27</xref>,<xref ref-type="bibr" rid="EHR504C31">31</xref></sup></p><p>There are two main limitations to our subanalysis of the FAIR-HF study. First, the study
was not originally powered for significant differences in terms of the various HRQoL summary
scores and domains, although the findings are consistent with the changes observed in the
two symptom-based primary endpoints of the FAIR-HF study (PGA and NYHA).<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> Second, the selection criteria could
limit the generalization of the results to the CHF population at large, although the
positive effects of FCM were observed in a wide range of different patient subgroups.</p><p>In our study, i.v. iron treatment was considered to be well tolerated.<sup><xref ref-type="bibr" rid="EHR504C19">19</xref></sup> However, it must be noted that long-term
safety data for treatment with this drug in the setting of CHF are currently lacking.
Studies evaluating longer periods of treatment, such as CONFIRM-HF (ClinicalTrials.gov
identifier: NCT01453608),<sup><xref ref-type="bibr" rid="EHR504C32">32</xref></sup> and
evaluation of the effect on mortality and morbidity would be desirable.</p><p>In conclusion, we have shown that iron repletion with FCM over a 24-week period improves
generic and disease-specific measures of HRQoL in stable, symptomatic, and ambulatory CHF
patients with ID and systolic dysfunction. The beneficial effects of FCM on patient-centred
outcomes were observed 4 weeks after initiation of therapy, and were independent of baseline
anaemia status and renal function. In addition to improvements, we observed less
deterioration in HRQoL in patients treated with FCM. Further research is required to confirm
these findings and to determine the underlying mechanisms of the efficacy of i.v. iron in
patients with ID and CHF.</p></sec><sec id="s5"><title>Funding</title><p>The FAIR-HF study was sponsored by Vifor Pharma Ltd. Funding to pay the statistical
support, the editorial assistance and the Open Access publication charges for this article
was provided by Vifor Pharma Ltd.</p><p><bold>Conflict of interest</bold>: S.D.A., P.P., J.C.C., G.F., R.W., K.D., and T.L. are
members of the FAIR-HF steering committee. S.D.A. and R.W. are consultants and have received
honoraria for speaking for Vifor Pharma Ltd and Amgen, Inc. S.D.A. has received honoraria
for speaking for Roche Pharma and Teva. J.C.C., G.F., and T.L. have received honoraria for
speaking for Vifor Pharma Ltd. P.P. is a consultant and has received honoraria for speaking
from Vifor Pharma Ltd. C.M. and P.J. are employees of Vifor Pharma Ltd., Switzerland and
hold stock in Galenica Ltd. M.L. received the Heart Failure Association Research
Fellowship.</p></sec></body><back><ack><title>Acknowledgements</title><p>The FAIR-HF was sponsored by Vifor-Pharma Ltd, Switzerland. Janne Harjunp&#x000e4;&#x000e4;
provided statistical support under the direction of Dr Comin-Colet. Dr David Floyd (formerly
Vifor Pharma Ltd., Glattbrugg, Switzerland) and Dr Linn Hjortsberg (Vifor Pharma Ltd,
Glattbrugg, Switzerland) provided editorial assistance in the preparation of this
manuscript.</p></ack><ref-list><title>References</title><ref id="EHR504C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvert</surname><given-names>MJ</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name></person-group><article-title>The impact of chronic heart failure on health-related quality of life data
acquired in the baseline phase of the CARE-HF study</article-title><source>Eur J Heart Fail</source><year>2005</year><volume>7</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">15701474</pub-id></element-citation></ref><ref id="EHR504C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juenger</surname><given-names>J</given-names></name><name><surname>Schellberg</surname><given-names>D</given-names></name><name><surname>Kraemer</surname><given-names>S</given-names></name><name><surname>Haunstetter</surname><given-names>A</given-names></name><name><surname>Zugck</surname><given-names>C</given-names></name><name><surname>Herzog</surname><given-names>W</given-names></name><name><surname>Haass</surname><given-names>M</given-names></name></person-group><article-title>Health related quality of life in patients with congestive heart failure:
comparison with other chronic diseases and relation to functional
variables</article-title><source>Heart</source><year>2002</year><volume>87</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">11847161</pub-id></element-citation></ref><ref id="EHR504C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>FD</given-names></name><name><surname>Kenkre</surname><given-names>JE</given-names></name><name><surname>Roalfe</surname><given-names>AK</given-names></name><name><surname>Davis</surname><given-names>RC</given-names></name><name><surname>Hare</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>MK</given-names></name></person-group><article-title>Impact of heart failure and left ventricular systolic dysfunction on
quality of life: a cross-sectional study comparing common chronic cardiac and medical
disorders and a representative adult population</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><fpage>1867</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">12445536</pub-id></element-citation></ref><ref id="EHR504C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name></person-group><article-title>Why does chronic heart failure cause breathlessness and
fatigue?</article-title><source>Prog Cardiovasc Dis</source><year>2007</year><volume>49</volume><fpage>366</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">17329182</pub-id></element-citation></ref><ref id="EHR504C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravely-Witte</surname><given-names>S</given-names></name><name><surname>Jurgens</surname><given-names>CY</given-names></name><name><surname>Tamim</surname><given-names>H</given-names></name><name><surname>Grace</surname><given-names>SL</given-names></name></person-group><article-title>Length of delay in seeking medical care by patients with heart failure
symptoms and the role of symptom-related factors: a narrative review</article-title><source>Eur J Heart Fail</source><year>2010</year><volume>12</volume><fpage>1122</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">20685686</pub-id></element-citation></ref><ref id="EHR504C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaarsma</surname><given-names>T</given-names></name><name><surname>Beattie</surname><given-names>JM</given-names></name><name><surname>Ryder</surname><given-names>M</given-names></name><name><surname>Rutten</surname><given-names>FH</given-names></name><name><surname>McDonagh</surname><given-names>T</given-names></name><name><surname>Mohacsi</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>SA</given-names></name><name><surname>Grodzicki</surname><given-names>T</given-names></name><name><surname>Bergh</surname><given-names>I</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Ekman</surname><given-names>I</given-names></name><name><surname>Angermann</surname><given-names>C</given-names></name><name><surname>Leventhal</surname><given-names>M</given-names></name><name><surname>Pitsis</surname><given-names>A</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Gavazzi</surname><given-names>A</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Delacretaz</surname><given-names>E</given-names></name><name><surname>Blue</surname><given-names>L</given-names></name><name><surname>Strasser</surname><given-names>F</given-names></name><name><surname>McMurray</surname><given-names>J</given-names></name></person-group><article-title>Palliative care in heart failure: a position statement from the palliative
care workshop of the Heart Failure Association of the European Society of
Cardiology</article-title><source>Eur J Heart Fail</source><year>2009</year><volume>11</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">19386813</pub-id></element-citation></ref><ref id="EHR504C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainscak</surname><given-names>M</given-names></name><name><surname>Blue</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name><name><surname>Dahlstrom</surname><given-names>U</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Ekman</surname><given-names>I</given-names></name><name><surname>McDonagh</surname><given-names>T</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Ryder</surname><given-names>M</given-names></name><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Stromberg</surname><given-names>A</given-names></name><name><surname>Jaarsma</surname><given-names>T</given-names></name></person-group><article-title>Self-care management of heart failure: practical recommendations from the
Patient Care Committee of the Heart Failure Association of the European Society of
Cardiology</article-title><source>Eur J Heart Fail</source><year>2011</year><volume>13</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">21148593</pub-id></element-citation></ref><ref id="EHR504C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>TA</given-names></name><name><surname>Blue</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name><name><surname>Dahlstrom</surname><given-names>U</given-names></name><name><surname>Ekman</surname><given-names>I</given-names></name><name><surname>Lainscak</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>K</given-names></name><name><surname>Ryder</surname><given-names>M</given-names></name><name><surname>Stromberg</surname><given-names>A</given-names></name><name><surname>Jaarsma</surname><given-names>T</given-names></name></person-group><article-title>European Society of Cardiology Heart Failure Association Standards for
delivering heart failure care</article-title><source>Eur J Heart Fail</source><year>2011</year><volume>13</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">21159794</pub-id></element-citation></ref><ref id="EHR504C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Calvert</surname><given-names>MJ</given-names></name><name><surname>Verboven</surname><given-names>Y</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name></person-group><article-title>Effects of cardiac resynchronization therapy on long-term quality of life:
an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF)
study</article-title><source>Am Heart J</source><year>2009</year><volume>157</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">19249415</pub-id></element-citation></ref><ref id="EHR504C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobre</surname><given-names>D</given-names></name><name><surname>van Jaarsveld</surname><given-names>CH</given-names></name><name><surname>deJongste</surname><given-names>MJ</given-names></name><name><surname>Haaijer Ruskamp</surname><given-names>FM</given-names></name><name><surname>Ranchor</surname><given-names>AV</given-names></name></person-group><article-title>The effect of beta-blocker therapy on quality of life in heart failure
patients: a systematic review and meta-analysis</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2007</year><volume>16</volume><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">16555368</pub-id></element-citation></ref><ref id="EHR504C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>JD</given-names></name><name><surname>Brownlie</surname><given-names>T</given-names></name></person-group><article-title>Iron deficiency and reduced work capacity: a critical review of the
research to determine a causal relationship</article-title><source>J Nutr</source><year>2001</year><volume>131</volume><issue>2</issue><fpage>676S</fpage><lpage>688S</lpage><comment>discussion 688S-690S</comment><pub-id pub-id-type="pmid">11160598</pub-id></element-citation></ref><ref id="EHR504C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beard</surname><given-names>JL</given-names></name></person-group><article-title>Iron biology in immune function, muscle metabolism and neuronal
functioning</article-title><source>J Nutr</source><year>2001</year><volume>131</volume><issue>2</issue><fpage>568S</fpage><lpage>579S</lpage><comment>discussion 580S</comment><pub-id pub-id-type="pmid">11160590</pub-id></element-citation></ref><ref id="EHR504C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowska</surname><given-names>EA</given-names></name><name><surname>Rozentryt</surname><given-names>P</given-names></name><name><surname>Witkowska</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>O</given-names></name><name><surname>Ponikowska</surname><given-names>B</given-names></name><name><surname>Borodulin-Nadzieja</surname><given-names>L</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><name><surname>Polonski</surname><given-names>L</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group><article-title>Iron deficiency: an ominous sign in patients with systolic chronic heart
failure</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>1872</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">20570952</pub-id></element-citation></ref><ref id="EHR504C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlie</surname><given-names>T</given-names><suffix>IV</suffix></name><name><surname>Utermohlen</surname><given-names>V</given-names></name><name><surname>Hinton</surname><given-names>PS</given-names></name><name><surname>Haas</surname><given-names>JD</given-names></name></person-group><article-title>Tissue iron deficiency without anemia impairs adaptation in endurance
capacity after aerobic training in previously untrained women</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>79</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">14985219</pub-id></element-citation></ref><ref id="EHR504C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdon</surname><given-names>F</given-names></name><name><surname>Burnand</surname><given-names>B</given-names></name><name><surname>Stubi</surname><given-names>CL</given-names></name><name><surname>Bonard</surname><given-names>C</given-names></name><name><surname>Graff</surname><given-names>M</given-names></name><name><surname>Michaud</surname><given-names>A</given-names></name><name><surname>Bischoff</surname><given-names>T</given-names></name><name><surname>de Vevey</surname><given-names>M</given-names></name><name><surname>Studer</surname><given-names>JP</given-names></name><name><surname>Herzig</surname><given-names>L</given-names></name><name><surname>Chapuis</surname><given-names>C</given-names></name><name><surname>Tissot</surname><given-names>J</given-names></name><name><surname>Pecoud</surname><given-names>A</given-names></name><name><surname>Favrat</surname><given-names>B</given-names></name></person-group><article-title>Iron supplementation for unexplained fatigue in non-anaemic women: double
blind randomised placebo controlled trial</article-title><source>BMJ</source><year>2003</year><volume>326</volume><fpage>1124</fpage><pub-id pub-id-type="pmid">12763985</pub-id></element-citation></ref><ref id="EHR504C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>A</given-names></name><name><surname>Natarajan</surname><given-names>S</given-names></name><name><surname>Lipsitz</surname><given-names>SR</given-names></name><name><surname>Katz</surname><given-names>SD</given-names></name></person-group><article-title>Iron deficiency in community-dwelling US adults with self-reported heart
failure in the National Health and Nutrition Examination Survey III: prevalence and
associations with anemia and inflammation</article-title><source>Circ Heart Fail</source><year>2011</year><volume>4</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">21705484</pub-id></element-citation></ref><ref id="EHR504C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowska</surname><given-names>EA</given-names></name><name><surname>Rozentryt</surname><given-names>P</given-names></name><name><surname>Witkowska</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>O</given-names></name><name><surname>Ponikowska</surname><given-names>B</given-names></name><name><surname>Borodulin-Nadzieja</surname><given-names>L</given-names></name><name><surname>von Haehling</surname><given-names>S</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><name><surname>Polonski</surname><given-names>L</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group><article-title>Iron deficiency predicts impaired exercise capacity in patients with
systolic chronic heart failure</article-title><source>J Card Fail</source><year>2011</year><volume>17</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">22041326</pub-id></element-citation></ref><ref id="EHR504C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Comin Colet</surname><given-names>J</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Willenheimer</surname><given-names>R</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Luscher</surname><given-names>TF</given-names></name><name><surname>Mori</surname><given-names>C</given-names></name><name><surname>von Eisenhart Rothe</surname><given-names>B</given-names></name><name><surname>Pocock</surname><given-names>S</given-names></name><name><surname>Poole-Wilson</surname><given-names>PA</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group><article-title>Rationale and design of Ferinject assessment in patients with IRon
deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled
study of intravenous iron supplementation in patients with and without
anaemia</article-title><source>Eur J Heart Fail</source><year>2009</year><volume>11</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">19875408</pub-id></element-citation></ref><ref id="EHR504C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Comin Colet</surname><given-names>J</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Willenheimer</surname><given-names>R</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Luscher</surname><given-names>TF</given-names></name><name><surname>Bart</surname><given-names>B</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><name><surname>Niegowska</surname><given-names>J</given-names></name><name><surname>Kirwan</surname><given-names>BA</given-names></name><name><surname>Mori</surname><given-names>C</given-names></name><name><surname>von Eisenhart Rothe</surname><given-names>B</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>Poole-Wilson</surname><given-names>PA</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group><article-title>Ferric carboxymaltose in patients with heart failure and iron
deficiency</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>2436</fpage><lpage>2448</lpage><pub-id pub-id-type="pmid">19920054</pub-id></element-citation></ref><ref id="EHR504C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>CP</given-names></name><name><surname>Porter</surname><given-names>CB</given-names></name><name><surname>Bresnahan</surname><given-names>DR</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name></person-group><article-title>Development and evaluation of the Kansas City Cardiomyopathy Questionnaire:
a new health status measure for heart failure</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>35</volume><fpage>1245</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">10758967</pub-id></element-citation></ref><ref id="EHR504C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spertus</surname><given-names>J</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Conard</surname><given-names>MW</given-names></name><name><surname>Heidenreich</surname><given-names>PA</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>McCullough</surname><given-names>PA</given-names></name><name><surname>Pina</surname><given-names>I</given-names></name><name><surname>Tooley</surname><given-names>J</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name></person-group><article-title>Monitoring clinical changes in patients with heart failure: a comparison of
methods</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><fpage>707</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">16209970</pub-id></element-citation></ref><ref id="EHR504C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>SJ</given-names></name><name><surname>Brazier</surname><given-names>JE</given-names></name></person-group><article-title>Comparison of the minimally important difference for two health state
utility measures: EQ-5D and SF-6D</article-title><source>Qual Life Res</source><year>2005</year><volume>14</volume><fpage>1523</fpage><lpage>1532</lpage><pub-id pub-id-type="pmid">16110932</pub-id></element-citation></ref><ref id="EHR504C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AP</given-names></name><name><surname>Bartlett</surname><given-names>FR</given-names></name><name><surname>Penston</surname><given-names>HS</given-names></name><name><surname>O'Leary</surname><given-names>J</given-names></name><name><surname>Pollock</surname><given-names>N</given-names></name><name><surname>Kaprielian</surname><given-names>R</given-names></name><name><surname>Chapman</surname><given-names>CM</given-names></name></person-group><article-title>Intravenous iron alone for the treatment of anemia in patients with chronic
heart failure</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>1225</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">16979010</pub-id></element-citation></ref><ref id="EHR504C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okonko</surname><given-names>DO</given-names></name><name><surname>Grzeslo</surname><given-names>A</given-names></name><name><surname>Witkowski</surname><given-names>T</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Slater</surname><given-names>RM</given-names></name><name><surname>Roughton</surname><given-names>M</given-names></name><name><surname>Foldes</surname><given-names>G</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name><name><surname>Majda</surname><given-names>J</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><name><surname>Missouris</surname><given-names>CG</given-names></name><name><surname>Poole-Wilson</surname><given-names>PA</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group><article-title>Effect of intravenous iron sucrose on exercise tolerance in anemic and
nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF:
a randomized, controlled, observer-blinded trial</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">18191732</pub-id></element-citation></ref><ref id="EHR504C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toblli</surname><given-names>JE</given-names></name><name><surname>Lombrana</surname><given-names>A</given-names></name><name><surname>Duarte</surname><given-names>P</given-names></name><name><surname>Di Gennaro</surname><given-names>F</given-names></name></person-group><article-title>Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic
patients with chronic heart failure and renal insufficiency</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>1657</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">17950147</pub-id></element-citation></ref><ref id="EHR504C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kind</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>P</given-names></name><name><surname>Gudex</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name></person-group><article-title>Variations in population health status: results from a United Kingdom
national questionnaire survey</article-title><source>BMJ</source><year>1998</year><volume>316</volume><fpage>736</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">9529408</pub-id></element-citation></ref><ref id="EHR504C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>MD</given-names></name><name><surname>Levy</surname><given-names>WC</given-names></name><name><surname>Russo</surname><given-names>JE</given-names></name><name><surname>Crane</surname><given-names>B</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name></person-group><article-title>Summary health status measures in advanced heart failure: relationship to
clinical variables and outcome</article-title><source>J Card Fail</source><year>2007</year><volume>13</volume><fpage>560</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">17826647</pub-id></element-citation></ref><ref id="EHR504C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punnonen</surname><given-names>K</given-names></name><name><surname>Irjala</surname><given-names>K</given-names></name><name><surname>Rajamaki</surname><given-names>A</given-names></name></person-group><article-title>Serum transferrin receptor and its ratio to serum ferritin in the diagnosis
of iron deficiency</article-title><source>Blood</source><year>1997</year><volume>89</volume><fpage>1052</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">9028338</pub-id></element-citation></ref><ref id="EHR504C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeder</surname><given-names>MT</given-names></name><name><surname>Khammy</surname><given-names>O</given-names></name><name><surname>Dos Remedios</surname><given-names>C</given-names></name><name><surname>Kaye</surname><given-names>DM</given-names></name></person-group><article-title>Myocardial and systemic iron depletion in heart failure implications for
anemia accompanying heart failure</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>58</volume><fpage>474</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">21777743</pub-id></element-citation></ref><ref id="EHR504C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usmanov</surname><given-names>RI</given-names></name><name><surname>Zueva</surname><given-names>EB</given-names></name><name><surname>Silverberg</surname><given-names>DS</given-names></name><name><surname>Shaked</surname><given-names>M</given-names></name></person-group><article-title>Intravenous iron without erythropoietin for the treatment of iron
deficiency anemia in patients with moderate to severe congestive heart failure and
chronic kidney insufficiency</article-title><source>J Nephrol</source><year>2008</year><volume>21</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">18446719</pub-id></element-citation></ref><ref id="EHR504C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>J</given-names></name><name><surname>Nabb</surname><given-names>S</given-names></name><name><surname>Zaletel-Kragelj</surname><given-names>L</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Lainscak</surname><given-names>M</given-names></name></person-group><article-title>Self-rated health and mortality in patients with chronic heart
failure</article-title><source>Eur J Heart Fail</source><year>2009</year><volume>11</volume><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">19329804</pub-id></element-citation></ref><ref id="EHR504C32"><label>32</label><element-citation publication-type="other"><collab>A Study to Compare the Use of Ferric Carboxymaltose with Placebo in Patients with
Chronic Heart Failure and Iron Deficiency (CONFIRM-HF)</collab><comment><uri xlink:type="simple" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01453608">http://clinicaltrials.gov/ct2/show/NCT01453608</uri> (23 January 2011)</comment></element-citation></ref></ref-list></back></article>